Sana Biotechnology announced that its CD19‑directed in‑vivo CAR T candidate SG293 has been accepted for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting in Boston, Massachusetts. The abstract will be presented on Tuesday, May 12, 2026, during the conference’s in‑vivo CAR T session.
SG293 employs Sana’s proprietary fusogen‑based delivery system to target CD8⁺ T cells and generate CAR T cells directly in the body. Preclinical studies demonstrate robust anti‑tumor activity in B‑cell lymphoma models and suggest potential applicability to B‑cell mediated autoimmune diseases. The acceptance of the abstract signals that the preclinical data are considered strong enough by the scientific community to merit a platform presentation, indicating progress toward clinical development.
The oral presentation provides Sana with a high‑profile forum to showcase its technology to the gene‑therapy community, potentially attracting partnership interest and reinforcing its position as a leader in the in‑vivo CAR T space. The event also highlights the company’s broader pipeline, which includes the SC451 program for type 1 diabetes that recently entered a strategic collaboration with the Mayo Clinic.
Sana’s pipeline strategy emphasizes rapid, cost‑effective cell therapies that eliminate the need for ex‑vivo manufacturing and lymphodepletion. The SG293 milestone aligns with this strategy and demonstrates the feasibility of the fusogen platform, strengthening investor confidence in the company’s long‑term growth prospects.
Overall, the abstract acceptance marks a key step in Sana’s journey toward bringing in‑vivo CAR T therapies to patients and underscores the company’s innovative approach to engineered cell medicines.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.